BioMarin shares hurt after mid-stage trial failure

Investors quickly shaved off about 15 percent of the value of BioMarin shares this morning after the developer announced that a drug program for hypertension had failed a mid-stage trial. BioMarin says that it plans to study the data on 6R-BH4, which failed to show a statistically significant advantage over a placebo, adding that it has no immediate plans to alter its planned development of the therapy. The candidate has the same active ingredient as Phenoptin, but the company says it works through a different mechanism and doesn't expect that the new data will have an impact on Phenoptin.

- here's the AP report on the data

Suggested Articles

Chi-Med has detailed plans to seek approval from the FDA later this year in part on the strength of data from Chinese phase 3 trial.

The clamor for more transparency from the leading pandemic vaccine contenders has been getting louder.

The role gives one of the driving forces behind Bristol Myers Squibb’s $74 billion takeover of Celgene the chance to help build biotechs.